HOME >> BIOLOGY >> NEWS
Jefferson scientists find gene expression pattern may predict behavior of leukemia

The expression pattern of certain genes may someday help doctors to diagnose and predict whether or not an individual has an aggressive form of B-cell chronic lymphocytic leukemia (CLL), Jefferson cancer researchers have found.

Scientists, led by Carlo Croce, M.D., director of Jefferson's Kimmel Cancer Center and professor and chair of microbiology and immunology at Jefferson Medical College of Thomas Jefferson University in Philadelphia, looked at the expression of genes that encoded microRNAs (miRNAs), tiny pieces of genetic material that are thought to be important in the regulation of gene expression and in the development of cancer. MiRNAs can serve as stop signs for gene expression and protein synthesis, and are thought to play important roles in regulating gene expression in development.

Reporting in both the online and the August 10 print version of the Proceedings of the National Academy of Sciences, the researchers taking advantage of a microarray chip Dr. Croce and his colleagues designed that carries all the known human miRNA genes compared the expression of miRNA genes in human CLL samples with that of normal white blood cells, or lymphocytes, called CD5+ B cells. CLL, the most common adult leukemia in the Western world, is characterized by an abnormal increase in the number of B cells.

"We found two specific genetic signatures," Dr. Croce says. One expression pattern of miRNA genes in CLL correlated with a deletion of a chromosomal region called 13q14. This region contained two small miRNA genes that are turned off in about 60 percent of CLL cases. The deletions at 13q14 represent an indicator of a good prognosis for the disease, he notes.

The other miRNA signature was associated with mutations in the Ig or immunoglobulin gene, which also indicates a good prognosis, says Dr. Croce. The researchers also found that the expression of one of the miRNA genes, miR-16, was reduced in both signatures.

"This suggests that CLL
'"/>


10-Aug-2004


Page: 1 2

Related biology news :

1. Jefferson Lab detector technology aids development of cystic fibrosis therapy
2. Jefferson researchers develop microchip to track genetic signature of cancer and normal tissue
3. Jefferson scientists use gene therapy to restore function of damaged heart cells in lab
4. Jefferson researchers uncover biochemical clues to how cells migrate in embryos
5. Jefferson and Brigham and Womens researchers find blue light important for setting biological clock
6. Jefferson Lab experiment generates THz radiation 20,000 times brighter than anyone else
7. Jefferson scientists show neural stem cells can become dopamine-making brain cells in laboratory
8. Jefferson scientists show how collagen gene mutation leads to osteoarthritis
9. Jefferson scientists use gene repair technique to change albino mice hairs to black
10. Jefferson scientists show drug is effective against a Hepatitis C Virus model in the laboratory
11. Jefferson scientists propose mechanism to control the bodys red blood cell and platelet production

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... Feb. 3, 2017 A new independent identity ... Partners, LLP (IdSP) . Designed to fill a critical ... identity market, founding partners Mark Crego and ... years just in identity expertise that span federal governments, ... leadership. The Crego-Kephart combined expertise has a common theme ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) ... oral peptide drug candidates, PTG-100 and PTG-200, at ... Crohn,s and Colitis Organization (ECCO).  The ECCO congress ... from February 15 – 18, 2017. ... on Protagonist drug candidates PTG-100 and PTG-200. PTG-100, ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, ... focused on venture growth investments in biotechnology and ... Josh Richardson , M.D. to Managing Director. ... companies.  He is a board observer at InfaCare ... Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... Feb. 16, 2017  Dermata Therapeutics, LLC, a ... treat a variety of dermatological diseases, today announced ... financing and entered into a $5 million credit ... to use the capital for general corporate purposes ... in the treatment of serious diseases treated by ...
Breaking Biology Technology:
Cached News: